跳至主要内容
临床试验/NCT02492477
NCT02492477终止1 期

TOP-TRIAL The Safety of Not Flushing the Non-used PORT-A-CATH® in Cancer Patients - a Prospective, Two-arm Phase I Trial, Pilot Trial

Krankenhaus Barmherzige Schwestern Linz1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2016年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
发起方
入组人数
4
试验地点
1
主要终点
incidences of PORT-A-CATH® related events (persistent malfunction, thrombosis, infection)

研究概览

简要总结

The benefits and risks of flushing or not flushing the non-used PORT-A-CATH® in cancer patients and the time interval of eventual PORT-A-CATH® flushing are currently unknown. The manufacturers of PORT-A-CATH® recommend regular flushings every 4 weeks. In clinical practice, the intervals are usually at least three months. Regular flushing might lead to a decreased risk of PORT-A-CATH® thrombosis, but may also lead to an increased infection or thrombosis rate and patients discomfort. Therefore, this study investigates the safety of not flushing the PORT-A-CATH® for 6 or 12 months.

详细描述

Currently it is unknown if flushing a non-used PORT-A-CATH® every 4 weeks is a valid strategy to preserve its functioning. Even more, decision to keep the PORT-A-CATH® after completion of adjuvant therapy cannot be based on profound patient information as there exist hardly any data regarding PORT-A-CATH® related complications of non-used PORT-A-CATH®.

The proposed prospective, two arm trial aims to investigate if no flushing of a non-used PORT-A-CATH® over a period of one year has equal PORT-A-CATH® related complications compared to flushing the PORT-A-CATH® every 4 weeks.

The proposed trial also aims to examine the frequencies of PORT-A-CATH® related complications in non-used PORT-A-CATH®. The authors put up the hypothesis that there will be fewer port-a-cath related infections in the experimental arms compared to the infection rate mentioned in the literature up to 27 %, since the puncture of the PORT-A-CATH® and the administration of fluids are the main causes of infection.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Cancer patients in curative setting, with port a cath Implantation for systemic chemotherapy, including neo-adjuvant and adjuvant chemo-immunotherapy and supportive therapy (e.g. parenteral Nutrition)
  • Completion of curative Treatment with port a cath indication, operation included, regardless of a non-intravenous (subcutaneous or oral) given therapy (endocrine therapy, chemo-immunotherapy, radiotherapy)
  • patients with pectoral port a cath systems
  • No port a cath associated complications during curative therapy such as investigated events: persistent malfunction, thrombosis, infection of the port-a-cath (to puncture the port a cath under X-ray control is allowed except it results in diangosis of persistent malfunction)
  • No therapeutic anticoagulant therapy (phenprocoumon/Marcoumar®, heparin)
  • No evidence of metastatic disease
  • ≥18 years
  • Willing to participate

排除标准

  • No signed informed consent
  • Patients with port a cath systems other than pectoral port a cath systems (e.g. forearm port a cath System)
  • Unable to attend control timepoints
  • Use of the port-a-cath after the above defined curative treatment (within the investigational period)
  • Willing to explant the port-a-cath
  • Willing to become pregnant within one year after adjuvant treatment
  • Patient with heparin-induced Thrombocytopenia (HIT)

研究组 & 干预措施

6 months

Experimental

evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase

干预措施: evaluation of PORT-A-CATH® (Procedure)

6 months

Experimental

evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase

干预措施: blocking with Medunasal®-Heparinblock (Drug)

6 months

Experimental

evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase

干预措施: restoration of PORT-A-CATH® with Alteplase (Drug)

12 months

Experimental

evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase

干预措施: evaluation of PORT-A-CATH® (Procedure)

12 months

Experimental

evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase

干预措施: blocking with Medunasal®-Heparinblock (Drug)

12 months

Experimental

evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase

干预措施: restoration of PORT-A-CATH® with Alteplase (Drug)

结局指标

主要结局

incidences of PORT-A-CATH® related events (persistent malfunction, thrombosis, infection)

时间窗: 6 or 12 months

次要结局

  • incidences of restoration of PORT-A-CATH® function by alteplase(6 or 12 months)
  • rate of necessary PORT-A-CATH® removal(6 or 12 months)

研究者

发起方
Krankenhaus Barmherzige Schwestern Linz
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

TOP-TRIAL Safety of Not Flushing Non-used... | 临床试验